Shares of Certara, Inc. (NASDAQ:CERT – Get Rating) reached a new 52-week low during trading on Thursday . The stock traded as low as $14.90 and last traded at $14.95, with a volume of 22563 shares trading hands. The stock had previously closed at $15.17.

Analysts Set New Price Targets

Several research firms recently commented on CERT. SVB Leerink decreased their price target on shares of Certara from $29.00 to $26.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 10th. Barclays decreased their price target on shares of Certara from $24.00 to $21.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 17th. Credit Suisse Group started coverage on shares of Certara in a research report on Wednesday, August 24th. They set an "outperform" rating and a $22.00 price objective for the company. Morgan Stanley cut their price objective on shares of Certara from $24.00 to $20.00 and set an "equal weight" rating for the company in a research report on Wednesday, August 24th. Finally, Berenberg Bank started coverage on shares of Certara in a research report on Thursday, September 8th. They set a "buy" rating and a $23.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $26.13.

Certara Price Performance

The stock has a market cap of $2.27 billion, a P/E ratio of -236.83, a PEG ratio of 0.94 and a beta of 1.27. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.51 and a quick ratio of 3.51. The business's fifty day moving average price is $19.09 and its 200 day moving average price is $19.77.

Insider Activity at Certara

In other Certara news, CFO Michael Andrew Schemick acquired 25,000 shares of the company's stock in a transaction that occurred on Wednesday, August 17th. The stock was acquired at an average price of $16.64 per share, for a total transaction of $416,000.00. Following the acquisition, the chief financial officer now directly owns 517,870 shares in the company, valued at $8,617,356.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Certara news, Director Stephen M. Mclean acquired 20,000 shares of the company's stock in a transaction that occurred on Friday, August 19th. The stock was acquired at an average price of $16.32 per share, for a total transaction of $326,400.00. Following the acquisition, the director now directly owns 42,000 shares in the company, valued at $685,440. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Michael Andrew Schemick acquired 25,000 shares of the company's stock in a transaction that occurred on Wednesday, August 17th. The stock was acquired at an average price of $16.64 per share, with a total value of $416,000.00. Following the acquisition, the chief financial officer now owns 517,870 shares in the company, valued at $8,617,356.80. The disclosure for this purchase can be found here. Insiders sold a total of 6,196,893 shares of company stock worth $107,705,300 in the last quarter. 4.02% of the stock is owned by insiders.

Institutional Trading of Certara

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CERT. First Horizon Advisors Inc. increased its position in Certara by 9,193.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,487 shares of the company's stock valued at $32,000 after purchasing an additional 1,471 shares during the period. Benjamin Edwards Inc. increased its position in Certara by 9,338.1% during the 1st quarter. Benjamin Edwards Inc. now owns 1,982 shares of the company's stock valued at $43,000 after purchasing an additional 1,961 shares during the period. Hardy Reed LLC acquired a new stake in Certara during the 1st quarter valued at approximately $89,000. Captrust Financial Advisors increased its position in Certara by 135.8% during the 1st quarter. Captrust Financial Advisors now owns 4,628 shares of the company's stock valued at $99,000 after purchasing an additional 2,665 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in Certara during the 1st quarter valued at approximately $111,000. Institutional investors and hedge funds own 77.42% of the company's stock.

Certara Company Profile

(Get Rating)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

Further Reading

• Get a free copy of the StockNews.com research report on Certara (CERT)
• Stock Market: 3 Islands Of Strength In A Sea Of Red
• 3 Banks Worth Considering For Q4
• Is There a Cure for What is Ailing Teladoc Stock?
• No One Told These 3 Stocks It's a Down Week
• MarketBeat: Week in Review 9/12 – 9/16

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.